KEYNOTE‐033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC von Ren, Shengxiang, Feng, Jifeng, Ma, Shenglin, Chen, HuaJun, Ma, Zhiyong, Huang, Cheng, Zhang, Li, He, Jianxing, Wang, Changli, Zhou, Jianying, Danchaivijtr, Pongwut, Wang, Chin‐Chou, Vynnychenko, Ihor, Wang, Kai, Orlandi, Francisco, Sriuranpong, Virote, Li, Ben, Ge, Jun, Dang, Thao, Zhou, Caicun

Volltext